Trial Profile
A multicentric, prospective, randomized, open label Phase IV clinical study to evaluate the safety and efficacy of Saroglitazar (ZYH1) as compared to fenofibrate in patients with dyslipidemia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary) ; Fenofibrate
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Therapeutic Use
- Acronyms PRESS X
- Sponsors Zydus Lifesciences
- 01 Jul 2022 Results (n=82) assessing to compare the efficacy and safety of saroglitazar (4 mg) with fenofibrate (160 mg) in patients with moderate to severe hypertriglyceridemia, published in the Journal of Lipid Research.
- 20 Aug 2013 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India.
- 03 Jul 2013 New trial record